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Introduction: International Collaborative Effort on Chronic Obstructive Lung Disease: 
  Exacerbation Risk Index Cohorts (ICE COLD ERIC) is a prospective cohort study with chronic 
obstructive pulmonary disease (COPD) patients from Switzerland and The Netherlands designed 
to develop and validate practical COPD risk indices that predict the clinical course of COPD 
patients in primary care. This paper describes the characteristics of the cohorts at baseline.
Material and methods: Standardized assessments included lung function, patient history, 
self-administered questionnaires, exercise capacity, and a venous blood sample for analysis of 
biomarkers and genetics.
Results: A total of 260 Dutch and 151 Swiss patients were included. Median age was 66 years, 
57% were male, 38% were current smokers, 55% were former smokers, and 76% had at least one 
and 40% had two or more comorbidities with cardiovascular disease being the most prevalent 
one. The use of any pulmonary and cardiovascular drugs was 84% and 66%, respectively. 
Although lung function results (median forced expiratory volume in 1 second [FEV1] was 59% 
of predicted) were similar across the two cohorts, Swiss patients reported better COPD-specific 
health-related quality of life (Chronic Respiratory Questionnaire) and had higher exercise 
capacity.
Discussion: COPD patients in the ICE COLD ERIC study represent a wide range of disease 
severities and the prevalence of multimorbidity is high. The rich variation in these primary care 
cohorts offers good opportunities to learn more about the clinical course of COPD.
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Introduction
Most patients with chronic obstructive pulmonary disease (COPD) are managed by 
general practitioners (GP). GPs face the challenge of providing effective health care 
for patients with a highly heterogeneous disease to reduce the great impact of COPD 
on patients’ lives. An important part of the management includes an evaluation of 
disease severity and its implications for the choice of treatments. Interestingly, GPs 
do not base the evaluation of COPD patients on lung function only but consider other 
prognostically important markers such as history of exacerbations or dyspnea.1,2 
Such practice is supported by evidence that shows that lung function incompletely 
reflects patients’ health state and is, in fact, associated only weakly with prognosis.2–6 
There is increasing agreement among experts that characterizing patients should be 
based on combinations of prognostically important characteristics such as frequency 
of exacerbations, exercise capacity, and dyspnea that better reflect the multifaceted 
nature of COPD than a single parameter.7
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An attractive approach for combining patient characteris-
tics are scores such as the BODE (body mass index, obstruc-
tion, dyspnea, and exercise capacity), ADO (age, dyspnea, and 
obstruction) or DOSE (dyspnea, obstruction, smoking status, 
and exacerbation frequency) indices.1,3,8 Such scores can be 
used to assess the risk for premature mortality or exacerbations 
and may guide therapeutic management. Unfortunately, there 
seems to be low awareness for these indices in primary care,9 
which may be due to the unavailability of some components 
such as the 6-minute walk distance or the lack of validation in 
primary care cohorts. The ADO and DOSE indices overcome 
some of these limitations by including only parameters easily 
available in primary care.1,8 However, GPs may also be inter-
ested in the prediction of the clinical course of their patients 
in terms of measures of symptoms and health-related quality 
of life. Therefore, disease severity indices for COPD patients 
should be developed or at least validated in primary care popu-
lations because they may reflect a COPD population that is 
different from many COPD cohorts that are mainly recruited 
in secondary and tertiary care centers. The International 
Collaborative Effort on Chronic Obstructive Lung Disease: 
Exacerbation Risk Index Cohorts (ICE COLD ERIC) study 
was designed to develop and validate such practical COPD 
severity indices in primary care patients with Global Initia-
tive for Chronic Obstructive Lung   Disease (GOLD) stages 
II–IV .10 This paper describes baseline characteristics and 
provides a detailed characterization of the ICE COLD ERIC   
cohorts.
Methods and design
ICE COLD ERIC is an international study in which two 
prospective cohort studies with primary care COPD patients 
(GOLD stages II–IV) from Switzerland and The Netherlands 
are linked. All included patients have provided written 
informed consent. The study has been approved of by all 
local ethics committees and is registered on ClinicalTrials.
gov (NCT00706602).
Population
Included patients are $40 years of age with COPD in 
GOLD stages II–IV who were able to complete the base-
line assessment and had been free of exacerbation for at 
least 4 weeks. Exclusion criteria were a life expectancy 
of #12 months, dementia, psychosis or other psychiatric 
morbidity that would invalidate assessment of patient-
reported parameters, and inability to complete the baseline 
assessment due to language difficulties. Patients were 
included between April 2008 and April 2009.
A single protocol for both countries was designed for the 
baseline assessment and follow-up assessments. To ensure 
comparability, we developed and pilot tested case report 
forms and instructions for testing. Investigators meet twice a 
year and have frequent telephone and email contact to ensure 
that the assessments remain similar in both countries. More 
details on the study protocol were reported elsewhere.10
Study design and methods
The baseline assessment10 consisted of lung function 
  measurement (forced expiratory volume in 1 second [FEV1], 
forced vital capacity [FVC], and inspiratory reserve   volume 
[IRV]) after bronchodilation with two puffs of 100 µg 
salbutamol through a spacer, a detailed patient history with 
general information (date of birth, sex, living situation, 
occupation, and education) and COPD-specific information 
(year of diagnosis, smoking history, current smoking, 
  exposure to smoke at home, exacerbations, chronic cough, 
and phlegm), detailed registration of comorbidities, and 
use of drugs and any nondrug treatments for COPD and 
other diseases (self-reported). It also included measure-
ment of BMI (as calculated by height/weight2). All patients 
completed several questionnaires. To assess dyspnea, they 
completed the Medical Research Council11 (MRC) dyspnea 
scale with a score of zero to four where zero is “no or little 
dyspnea associated with heavy physical activity” and four 
is “too breathless to leave the house or breathless when (un)
dressing.” For COPD-specific health-related quality of life, 
the Chronic Respiratory Questionnaire (CRQ) was used.12–14 
The CRQ provides scores in four different domains   (dyspnea, 
fatigue, emotional, and mastery) each on a scale of one to 
seven, where one is the worst score indicating very poor 
health-related quality of life and seven the best. Patients 
scored their health on the Feeling Thermometer,15–17 a scale of   
zero (very bad) to 100 (very good) and they answered three   
questions for measuring self-efficacy, the patient’s belief in 
his or her skills to manage the illness. A short COPD-specific 
instrument was used to measure the patient’s self-efficacy. It 
contained three questions for coping with COPD, dyspnea, 
and the use of pulmonary drugs, respectively, on a five-
point scale from one (not confident) to five (very confident). 
Finally, the hospital anxiety and depression scale18,19 (HADS)   
was used to provide scores for depression and anxiety. Scores 
above eight indicate that a depression and/or anxiety disorder 
is likely to be present. Two tests were performed to measure 
exercise capacity, the sit-to-stand test and the handgrip 
strength test. During the sit-to-stand test patients hold their 
hands on their hips and they complete the sitting and standing   
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positions on a chair without arm rests for 1 minute as   correctly 
and as fully as possible without using the arms for support.20 
The handgrip test is used to assess grip strength of both 
hands with the Jamar® Hydraulic Hand Dynamometer (JA 
Preston Corporation, Jackson, MI).21 A blood sample was 
taken from each patient to measure creatinine, bilirubin, 
alanine-aminotransferase, total cholesterol, high-density 
lipoprotein cholesterol, low-density lipoprotein cholesterol, 
triglycerides, C-reactive protein, carboxyhemoglobin, and 
leukocytes. A differential blood count was performed and 
DNA was extracted and stored at −80°C. Finally, for every 
patient, ADO and DOSE indices were calculated.1,8 The ADO 
index estimates the 3-year mortality risk and the DOSE index 
estimates health status. Of note, the ability of the ADO and 
DOSE indices to predict mortality, exacerbations, and health 
status in these populations will be reported when follow-up 
assessments are completed.
Statistical analysis
Summary statistics were calculated for all variables. Percent-
ages and absolute numbers are used to describe dichotomous 
and categorical variables. Median, fifth percentile, and 95th 
percentile are used to describe continuous variables. The 
fifth percentile means that only 5% of the observed values 
is lower than that value and the 95th percentile means that 
95% is lower than that value (and only 5% higher). Data were 
analyzed using Stata software (v 10.1; StataCorp, College 
Station, TX).
Results
Table 1 summarizes general and COPD-specific patient 
characteristics. Male/female ratio was 50/50 for the Dutch 
and 68/32 for the Swiss cohort. The median age was 66 years 
in the Dutch and 67 years in the Swiss cohort. Half of the 
patients in both cohorts had a diagnosis of COPD for less 
than 5 years and 19% of the Swiss and 9% of the Dutch 
patients had this diagnosis for less than 1 year. The median 
number of pack years was 37 for the Dutch and 45 for the 
Swiss cohort. The percentage of smokers vs former smokers 
was 40% vs 53% for the Dutch cohort and 35% vs 58% for 
the Swiss cohort. Four percent of the Dutch cohort reported 
they had never smoked in their life vs 6% of the Swiss cohort. 
Around 33% of patients had one or more exacerbations in the 
previous year. The median MRC score was 2.5 for the Dutch 
and one for the Swiss cohort; 39% of the Dutch cohort had 
the maximum (worst) MRC score vs 0% of the Swiss cohort. 
Median, fifth, and 95th percentiles of MRC scores for each 
of the three GOLD categories were also calculated.
Figure 1 shows the frequencies of comorbidities and of 
their simultaneous presence. These Venn diagrams show 
comorbidities and multimorbidities for the Dutch cohort, 
the Swiss cohort, and the total cohort. The diagrams are 
next to each other, the sharing of the cells is similar, and the 
  percentages in the cells represent the (overlap of) comorbidity, 
which makes it easy to compare the cohorts with each other. 
Group A (black) represents cardiovascular disease consisting 
of coronary artery disease, chronic heart failure, and cerebro-
vascular disease. Group B (red) represents type 1 and type 2 
diabetes mellitus. Group C (blue) represents musculoskeletal 
disease, mainly osteoarthritis and rheumatoid arthritis. Group 
D (green) represents other comorbidities such as asthma, 
malignancies, and infectious disease.
As shown in Table 2, 88% of the Dutch cohort used pul-
monary drugs vs 76% of the Swiss cohort with the   highest 
percentages for inhaled corticosteroids and long-acting 
beta-agonists. Around 14% used antidiabetic drugs, usually 
oral antidiabetics, and 66% had at least one cardiovascular 
drug, usually anticlotting. Around 40% in both cohorts had 
nondrug interventions, mainly physical exercise. Around 
8% in the Dutch cohort and 10% in the Swiss cohort had 
pulmonary rehabilitation.
In all CRQ domains Swiss patients had higher scores 
than Dutch patients (Table 3). HADS anxiety scores were 
quite similar whereas the HADS depression scores indicated 
more symptoms of depression in the Dutch cohort compared 
to the Swiss cohort. As expected, the CRQ dyspnea domain 
patients in higher GOLD categories had more dyspnea. 
For the other CRQ domains, Feeling Thermometer and 
HADS, the differences between patients in different GOLD 
categories were small.
In both exercise capacity tests the Swiss cohort showed 
higher exercise capacity than the Dutch cohort (Table 4). For 
the sit-to-stand test, differences were small between GOLD 
categories and no difference between GOLD categories for 
the hand grip test results was observed. The median score 
on the ADO index was five for the Dutch cohort and three 
for the Swiss, meaning that the Dutch had a higher risk 
of 3-year mortality than the Swiss, 16.3% (fifth to 95th 
  percentile: 7.9%–26.5%) vs 11.5% (fifth to 95th percentile: 
7.9%–19.3%). The median score on the DOSE-index was two 
for the Dutch cohort and one for the Swiss cohort, suggesting 
that Swiss patients had a better health status (as measured by 
the CCQ total score) than the Dutch.
The median values of FEV1 percentage (FEV1%) of pre-
dicted were 58% and 59% and FEV1/FVC ratio were 0.52 
and 0.57 for the Dutch and the Swiss cohort, respectively 
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Table 1 Patient characteristics of 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort N = 411) 
enrolled in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts prospective 
cohort study
Dutch cohort  
n, (%)
Swiss cohort  
n, (%)
Total cohort   
n, (%)
Sex 
  Male 
  Female
 
130 (50.0) 
130 (50.0)
 
103 (68.2) 
48 (31.8)
 
233 (56.7) 
178 (43.3)
Age 
  p5, p50, p95
 
51, 66, 83
 
52, 67, 81
 
51, 66, 82
BMI 
  p5, p50, p95
 
18.8, 25.5, 35.8
 
19.8, 25.2, 35.1
 
19.5, 25.4, 35.1
Living situation 
  Alone 
  With partner 
  With children 
  With partner and children 
  Unknown
 
103 (39.6) 
117 (45.0) 
12 (4.6) 
28 (10.8) 
0 (0.0)
 
46 (30.5) 
95 (62.9) 
3 (2.0) 
5 (3.3) 
2 (1.3)
 
149 (36.3) 
212 (51.6) 
15 (3.6) 
33 (8.0) 
2 (0.5)
Profession 
  Working 
  House wife 
  Retired 
  Disabled 
  Unemployed
 
53 (20.4) 
21 (8.1) 
132 (50.8) 
53 (20.4) 
1 (0.4)
 
36 (23.8) 
1 (0.7) 
106 (70.2) 
8 (5.3) 
0 (0.0)
 
89 (21.7) 
22 (5.4) 
238 (57.9) 
61 (14.8) 
1 (0.2)
Highest education 
  Primary school 
  Secondary school 
  Intermediate vocational 
  Higher vocational/university 
  Unknown
 
57 (21.9) 
115 (44.2) 
53 (20.4) 
34 (13.1) 
1 (0.4)
 
21 (13.9) 
105 (69.5) 
15 (9.9) 
6 (4.0) 
4 (2.6)
 
78 (19.0) 
220 (53.5) 
68 (16.5) 
40 (9.7) 
5 (1.2)
Diagnosis of COPD since 
  ,1 year 
  1–5 years 
  5–10 years 
  .10 years 
  Unknown
 
23 (8.8) 
102 (39.2) 
48 (18.5) 
65 (25.0) 
22 (8.5)
 
29 (19.2) 
45 (29.8) 
27 (17.9) 
42 (27.8) 
8 (5.3)
 
52 (12.6) 
147 (35.8) 
75 (18.2) 
107 (26.0) 
30 (7.3)
Pack years 
  p5, p50, p95
 
1, 37, 82
 
0, 45, 110
 
1, 40, 90
Smoking habits 
  Nonsmoker 
  Former smoker 
  Current smoker 
  Cigarettes per day 
    p5, p50, p95 
  Passive smoker 
  Cigar smoker 
  Pipe smoker
 
10 (3.9) 
137 (52.7) 
104 (40.0) 
 
3, 15, 40 
11 (4.2) 
8 (3.1) 
4 (1.5)
 
9 (6.0) 
87 (57.6) 
53 (35.1) 
 
3, 20, 50 
28 (18.5) 
4 (2.7) 
6 (4.0)
 
19 (4.6) 
224 (54.5) 
157 (38.2) 
 
3, 15, 40 
39 (9.5) 
12 (2.9) 
10 (2.4)
Exacerbations treated at home 
 0  
  1–2 
  .2 
  Unknown
 
171 (65.8) 
75 (28.8) 
14 (5.4) 
0 (0.0)
 
102 (67.5) 
47 (31.1) 
1 (0.7) 
1 (0.7)
 
273 (66.4) 
122 (29.7) 
15 (3.6) 
1 (0.2)
Exacerbations treated in hospital 
 0  
  1–2 
  .2 
  Unknown
 
248 (95.4) 
11 (4.2) 
1 (0.4) 
1 (0.0)
 
137 (90.7) 
12 (7.9) 
1 (0.7) 
1 (0.7)
 
385 (93.7) 
23 (5.6) 
2 (0.5) 
1 (0.2)
(Continued)
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Table 1 (Continued)
Dutch cohort  
n, (%)
Swiss cohort  
n, (%)
Total cohort   
n, (%)
MRC score 
  p5, p50, p95 
  GOLD II 
  GOLD III
 
0, 2.5, 4 
0, 1, 4 
1, 4, 4
 
0, 1, 3 
0, 1, 2 
0, 1, 3
 
0, 1, 4 
0, 1, 4 
1, 2, 4
  GOLD IV 
 0  
 1  
 2  
 3  
 4
1, 4, 4 
37 (14.2) 
77 (29.6) 
16 (6.2) 
28 (10.8) 
102 (39.2)
1, 2, 3 
34 (22.5) 
78 (51.7) 
25 (16.6) 
14 (9.3) 
0 (0.0)
1, 3, 4 
71 (17.3) 
155 (37.7) 
41 (10.0) 
42 (10.2) 
102 (24.8)
Chronic cough 
  Yes 
  No
 
122 (46.9) 
138 (53.1)
 
79 (52.3) 
72 (47.7)
 
201 (48.9) 
210 (51.1)
Chronic phlegm 
  Yes 
  No 
  Unknown
 
120 (46.2) 
139 (53.5) 
1 (0.4)
 
79 (52.3) 
70 (46.4) 
2 (1.3)
 
199 (48.4) 
209 (50.9) 
3 (0.7)
Notes: MRC score is divided into five categories: 0 = breathless with strenuous exercise, 1 = breathless when hurrying or walking up a slight hill, 2 = walks slower than 
other people of the same age because of breathlessness or has to stop for breath when walking at own pace, 3 = has to stop for breath after walking 100 yards or after a 
few minutes, 4 = too breathless to leave the house or breathless while (un)dressing. Numbers in GOLD stage II, III, and IV are 174, 64, and 22 for Dutch, 95, 40, and 16 for 
Swiss, and 269, 104, and 38 for total cohort.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; MRC, medical 
research council; p5, fifth percentile, p50, median, p95, 95th percentile.
C
D
Total cohort
A
B
30%
15%
36%
50%
7%
2%
9%
18%
3%
3% 
7%
1%
3%
12%
1%
1%
5%  ← 2% 2%
24%
C
Dutch cohort 
A
B
C
D
30%
17%
23%
35%
11%
4%
9%
16%
5%
 3% 
7%
1%
3%
5%
1%
1%
2%  ← 1% 0%
30% Swiss cohort
A
B
D
29%
13%
58%
74%
9%
20%
1%
2% 
7 %
1%
1%
25%
1%
1%
12% ← 3% 5%
12%
0%
0%
Figure 1 Comorbidities in Venn diagrams of 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort N = 411) enrolled in the International 
Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts prospective cohort study. The A box represents cardiovascular disease, 
B represents diabetes mellitus, C represents musculoskeletal disease and D represents other comorbidity. The different boxes with percentages show the overlap of 
comorbidity. For example, the three cells with arrows show the percentages that fall in group A, C, and D meaning the patient has cardiovascular disease AND musculoskeletal 
disease AND other comorbidity, but NOT diabetes mellitus. The sharing of the cells is identical in all three subdiagrams to facilitate the comparison of percentages. For 
example, the cells with the arrows can be easily compared: 2% in the Dutch cohort versus 12% in the Swiss cohort versus 5% in the total cohort.
(Table 5). The percentage of A-quality (best) for lung 
function measurement was 62% for the Dutch and 38% for 
the Swiss cohort. The GOLD classification was as follows: 
in the Dutch cohort 67% was classified as GOLD stage II, 
25% as GOLD stage III, and 9% as GOLD stage IV . In the 
Swiss cohort 63% was classified as GOLD stage II, 27% as 
GOLD stage III, and 11% as GOLD stage IV . Laboratory 
results are shown in Table 6.
Discussion
The analysis of these cohorts indicates that the impact of 
COPD was quite different in the Dutch and the Swiss cohort 
although lung function and the prevalence of comorbidity and 
multimorbidity were quite similar. Swiss patients reported 
higher scores on all CRQ domains than Dutch patients and 
for all domains these differences were 0.5 or higher (minimal 
important difference = 0.5),14 indicating that the Swiss 
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Table 2 Drug and nondrug interventions of 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort 
N = 411) enrolled in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts 
prospective cohort study
Dutch cohort  
n, (%)
Swiss cohort  
n, (%)
Total cohort   
n, (%)
No drugs at all 6 (2.3) 6 (4.0) 12 (2.9)
Pulmonary drugs 
  Ipratropium 
  Local steroids 
  Long-acting beta-agonists 
  Short acting beta-agonists 
  Tiotropium 
  Systemic steroids 
  Parasympaticolytics
229 (88.1) 
41 (17.9) 
164 (71.6) 
169 (73.8) 
80 (34.9) 
111 (48.5) 
11 (4.8) 
2 (0.9)
115 (76.2) 
12 (10.4) 
74 (64.3) 
76 (66.1) 
39 (33.9) 
45 (39.1) 
10 (8.7) 
1 (0.9)
344 (83.7) 
53 (15.4) 
238 (69.2) 
245 (71.2) 
119 (34.6) 
156 (45.3) 
21 (6.1) 
3 (0.9)
Cardiovascular drugs 
  ACE inhibitors 
  Anticlotting 
  Angiotensin-2-receptor inhibitors 
  Beta-antagonists 
  Calcium-antagonists 
  Diuretics 
  Statins
172 (66.2) 
79 (45.9) 
93 (54.1) 
19 (11.0) 
57 (33.1) 
34 (19.8) 
77 (44.8) 
86 (50.0)
101 (66.9) 
37 (36.6) 
65 (64.4) 
23 (22.8) 
37 (36.6) 
19 (18.8) 
48 (47.5) 
34 (33.7)
273 (66.4) 
116 (42.5) 
158 (57.9) 
42 (15.4) 
94 (34.4) 
53 (19.4) 
125 (45.8) 
120 (44.0)
Antidiabetic drugs 
  Oral antidiabetics 
  Insulin
38 (14.6) 
25 (65.8) 
13 (34.2)
21 (13.9) 
11 (52.4) 
9 (42.9)
59 (14.4) 
36 (61.0) 
22 (37.3)
Analgesia 
  NSAIDs 
  Other
38 (14.6) 
14 (36.8) 
21 (55.3)
30 (19.9) 
11 (36.7) 
14 (46.7)
68 (16.6) 
25 (36.8) 
35 (51.5)
Psychiatric drugs 
  Antidepressives 
  Anxiolytics/sedative/sleep
59 (22.7) 
25 (42.4) 
42 (71.2)
30 (19.9) 
17 (56.7) 
15 (50.0)
89 (21.7) 
42 (47.2) 
57 (64.0)
Other drugs 165 (63.5) 73 (48.3) 238 (57.9)
Nondrug therapies 
  Long-term oxygen treatment 
  Oxygen during exertion 
  Fitness training at home 
  Fitness training in a program 
  Lung volume reduction surgery 
  Pulmonary rehabilitation in the last year 
  Pulmonary rehabilitation .1 year ago 
  Devices 
  Other
100 (38.5) 
7 (7.0) 
3 (3.0) 
15 (15.0) 
37 (37.0) 
0 (0.0) 
1 (1.0) 
7 (7.0) 
62 (23.8) 
4 (4.0)
60 (39.7) 
5 (8.3) 
1 (1.7) 
37 (61.7) 
23 (38.3) 
2 (3.3) 
6 (10.0) 
0 (0.0) 
2 (3.3) 
7 (11.7)
160 (38.9) 
12 (7.5) 
4 (2.5) 
52 (32.5) 
60 (37.5) 
2 (1.3) 
7 (4.4) 
7 (4.4) 
64 (40.0) 
11 (6.9)
Abbreviations: ACE, angiotensin-converting enzyme; NSAIDs, nonsteroidal antiinflammatory drugs.
patients reported better COPD-specific health-related quality 
of life. On classifying patients according to GOLD category, 
these differences became even larger. This is also reflected 
in MRC scores where Dutch patients reported more dyspnea 
than Swiss patients. In both exercise tests, the Swiss patients 
showed higher exercise capacity than the Dutch patients. 
And, the Swiss cohort had a lower 3-year risk of mortality 
than the Dutch cohort, 11.5% vs 16.3%.
Approximately 50% of all patients received their COPD 
diagnosis less than 5 years ago. Of these, 9% of the Dutch 
patients and 19% of the Swiss had their COPD diagnosis 
for less than 1 year and were probably diagnosed as a result 
of their participation in this study. The fact that more Swiss 
patients were diagnosed within this study may be explained 
by differences in the identification and recruitment process 
between Switzerland and The Netherlands.10 In Switzerland, 
GPs known to have an active interest in research activities were 
involved and, through them, more GPs potentially willing to 
participate were identified (snowball approach).   Participating 
GPs identified potentially eligible patients through electronic 
or paper-based patient charts. For electronic patient charts GPs 
searched with the key terms “COPD,” “chronic bronchitis,” 
“emphysema,” “asthma,” and a combination of “smoking,” 
“$40 years of age,” and “male” to identify patients with 
COPD. Paper-based patient charts were screened by hand. 
Potentially eligible patients were informed about the study and 
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Table 3 Patient-reported outcomes of 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort N = 411) enrolled 
in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts prospective cohort study
Dutch cohort Swiss cohort Total cohort
CRQ 
  Dyspnea 
    GOLD II 
    GOLD III 
    GOLD IV 
  Fatigue 
    GOLD II 
    GOLD III 
    GOLD IV 
  Emotional 
    GOLD II 
    GOLD III 
    GOLD IV 
  Mastery 
    GOLD II 
    GOLD III 
    GOLD IV
 
p5, p50, p95 
 
 
 
p5, p50, p95 
 
 
 
p5, p50, p95 
 
 
 
p5, p50, p95
 
2.0, 4.5, 7.0 
2.2, 5.2, 7.0 
2.0, 3.7, 6.8 
1.0, 3.1, 7.0 
1.8, 4.0, 6.5 
1.8, 4.3, 6.5 
1.5, 4.0, 6.5 
1.5, 3.8, 5.8 
2.7, 5.1, 6.9 
2.7, 5.1, 6.7 
3.1, 5.3, 6.9 
2.7, 5.1, 6.9 
3.3, 5.5, 7.0 
3.0, 5.8, 7.0 
3.8, 5.5, 7.0 
3.3, 5.5, 6.8
 
2.8, 5.0, 7.0 
3.2, 5.5, 7.0 
3.0, 4.4, 6.7 
2.2, 4.4, 6.4 
2.5, 5.3, 6.5 
2.5, 5.3, 6.5 
2.4, 4.8, 6.0 
2.5, 5.4, 6.5 
3.0, 5.6, 6.7 
2.9, 5.6, 6.6 
3.5, 5.5, 6.5 
2.6, 5.8, 7.0 
3.5, 6.0, 7.0 
3.5, 6.0, 7.0 
3.3, 5.6, 6.9 
2.8, 6.1, 7.0
 
2.2, 4.8, 7.0 
2.5, 5.3, 7.0 
2.2, 4.0, 6.8 
1.0, 3.2, 7.0 
2.0, 4.5, 6.5 
2.0, 4.5, 6.5 
2.0, 4.3, 6.0 
1.5, 4.0, 6.3 
2.7, 5.4, 6.7 
2.7, 5.4, 6.7 
3.3, 5.4, 6.9 
2.6, 5.5, 6.9 
3.3, 5.8, 7.0 
3.3, 5.8, 7.0 
3.8, 5.5, 7.0 
3.0, 5.8, 7.0
HADS 
  Depression 
    GOLD II 
    GOLD III 
    GOLD IV 
    Scores above 8 
  Anxiety 
    GOLD II 
    GOLD III 
    GOLD IV 
    Scores above 8
 
p5, p50, p95 
 
 
 
n (%) 
p5, p50, p95 
 
 
 
n (%)
 
1, 5, 12 
1, 5, 11 
1, 5, 12 
2, 6, 12 
58 (22.5) 
0, 4, 13 
0, 5, 14 
0, 4, 12 
0, 5, 13 
53 (20.5)
 
1, 4, 10 
0, 4, 10 
1, 4, 10 
1, 4, 11 
13 (8.7) 
0, 3, 12 
0, 3, 12 
1, 3, 9 
0, 2, 15 
13 (8.8)
 
1, 5, 11 
0, 5, 11 
1, 4, 11 
1, 6, 12 
71 (17.4) 
0, 4, 13 
0, 4, 13 
0, 3, 10 
0, 5, 14 
66 (16.3)
Self efficacy 
  Illness 
    GOLD II 
    GOLD III 
    GOLD IV 
  Dyspnea 
    GOLD II 
    GOLD III 
    GOLD IV 
  Medication 
    GOLD II 
    GOLD III 
    GOLD IV
 
p5, p50, p95 
 
 
 
p5, p50, p95 
 
 
 
p5, p50, p95
 
2, 4, 5 
2, 4, 5 
2, 4, 5 
2, 4, 5 
1, 4, 5 
1, 4, 5 
2, 4, 5 
1, 3, 5 
2, 5, 5 
2, 5, 5 
4, 5, 5 
2, 5, 5
 
2, 4, 5 
3, 4, 5 
1, 4, 5 
1, 5, 5 
2, 4, 5 
2, 4, 5 
1, 4, 5 
2, 4, 5 
1, 5, 5 
1, 4, 5 
1, 5, 5 
1, 5, 5
 
2, 4, 5 
3, 4, 5 
2, 4, 5 
2, 4, 5 
1, 4, 5 
2, 4, 5 
2, 4, 5 
1, 3, 5 
1, 5, 5 
1, 5, 5 
2, 5, 5 
2, 5, 5
Feeling thermometer 
    GOLD II 
    GOLD III 
    GOLD IV
p5, p50, p95 44, 70, 93 
45, 70, 95 
47, 68, 80 
40, 60, 70
40, 75, 95 
50, 75, 95 
40, 65, 85 
4, 63, 90
43, 70, 95 
45, 70, 95 
47, 65, 85 
7, 60, 88
Notes: CRQ on a scale of one (worst) to seven (best). HADS score . 8 means anxiety/depression likely. Self efficacy questions on a scale of one (worst) to five (best). Feeling 
thermometer on a scale of zero (very bad health) to 100 (very good health). Numbers in GOLD stage II, III, and IV are 174, 64, and 22 for Dutch, 95, 40, and 16 for Swiss, and 
269, 104, and 38 for total cohort.
Abbreviations: CRQ, Chronic Respiratory Questionnaire; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HADS, hospital anxiety and depression scale; 
p5, fifth percentile; p50, median; p95, 95th percentile.
invited by telephone for eligibility testing. In The Netherlands, 
COPD patients were identified from primary health care cen-
ters registered in the GP research network of the Department 
of General Practice of the University of Amsterdam in Almere 
and Amsterdam. These patients received study information and 
an invitation letter from their GP. Patients who were not inter-
ested in participating or who did not wish to receive a phone 
call returned a reply card indicating as much. All patients who 
did not respond via the reply card were invited by telephone 
for eligibility testing.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
279
Characteristics of Dutch and Swiss primary care COPD patientsClinical Epidemiology 2011:3
Table 4 Exercise capacity and age, dyspnea, and obstruction index among 260 Dutch and 151 Swiss chronic obstructive pulmonary 
disease patients (total cohort N = 411) enrolled in the International Collaborative Effort on Chronic Obstructive Lung Disease: 
Exacerbation Risk Index Cohorts prospective cohort study
Dutch cohort Swiss cohort Total cohort
Sit-to-stand test (x/minute) 
    GOLD II 
    GOLD III 
    GOLD IV
p5, p50, p95 0, 14, 24 
0, 15, 25 
0, 15, 23 
0, 10, 17
11, 22, 40 
12, 23, 40 
0, 20, 42 
13, 18, 30
0, 17, 35 
0, 18, 35 
0, 17, 39 
0, 13, 26
Hand grip test 
  Right hand (kg) 
    GOLD II 
    GOLD III 
    GOLD IV 
  Left hand (kg) 
    GOLD II 
    GOLD III 
    GOLD IV
 
p5, p50, p95 
 
 
 
p5, p50, p95
 
16, 30, 52 
15, 30, 54 
18, 32, 49 
16, 30, 50 
12, 28, 50 
12, 28, 50 
14, 30, 50 
14, 27, 48
 
20, 40, 58 
18, 40, 58 
21, 40, 66 
20, 41, 54 
20, 36, 54 
20, 36, 56 
18, 35, 54 
16, 37, 50
 
18, 32, 56 
17, 32, 56 
18, 34, 56 
16, 36, 53 
14, 32, 52 
14, 32, 52 
16, 32, 53 
14, 29, 50
ADO index p5, p50, p95 1, 5, 8 1, 3, 6 1, 4, 7
DOSE index p5, p50, p95 0, 2, 6 0, 1, 4 0, 1, 5
Notes: ADO index is an estimation of 3-year risk of mortality. A score of five indicates a 3-year risk of mortality of 16.3%, score of 3 indicates a 3-year risk of mortality of 
11.5%, and score of four indicates a 3-year risk of mortality of 13.7%. DOSE index is an estimation of health status as measured by the CCQ total score. Numbers in GOLD 
stage II, III, and IV are 174, 64, and 22 for Dutch, 95, 40, and 16 for Swiss, and 269, 104, and 38 for total cohort.
Abbreviations: ADO, age, dyspnea and obstruction; DOSE, dyspnea, obstruction, smoking status, and exacerbation frequency; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease; p5, fifth percentile; p50, median; p95, 95th percentile.
Table 5 Lung function among 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort N = 411) enrolled 
in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts prospective cohort 
study
Dutch cohort Swiss cohort Total cohort
FEV1 (l) p5, p50, p95 0.64, 1.44, 2.56 0.63, 1.50, 2.47 0.63, 1.45, 2.56
FEV1, % of predicted p5, p50, p95 26, 58, 77 24, 59, 79 25, 59, 78
FVC (l) p5, p50, p95 1.66, 2.84, 4.55 1.43, 2.84, 4.42 1.56, 2.84, 4.48
FVC, % of predicted p5, p50, p95 57, 90, 118 53, 84, 117 55, 88, 118
FEV1/FVC p5, p50, p95 0.29, 0.52, 0.67 0.31, 0.57, 0.70 0.29, 0.53, 0.68
Inspiratory capacity p5, p50, p95 0.95, 2.13, 3.68 1.32, 2.39, 3.63 1.13, 2.23, 3.63
Quality of measurement  A 162 (62.3) 58 (38.4) 220 (53.5)
n (%) B 64 (24.6) 22 (14.6) 86 (20.9)
C 34 (13.1) 36 (23.8) 70 (17.0)
D 0 (0.0) 34 (22.5) 34 (8.3)
Less than D 0 (0.0) 1 (0.7) 1 (0.2)
GOLD II (50 # FEV% , 80)  
n (%)
174 (66.9) 95 (62.9) 269 (65.5)
GOLD III (30 # FEV% , 50)  
n (%)
64 (24.6) 40 (26.5) 104 (25.3)
GOLD IV (FEV1% , 30)  
n (%)
22 (8.5) 16 (10.6) 38 (9.3)
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; p5, fifth percentile; 
p50, median; p95, 95th percentile.
In terms of the lung function measurement that 
was performed at study entry, the quality was better in 
The   Netherlands than in Switzerland despite identical 
devices and a single protocol. It looks as if the number of 
measurement repetitions was lower in Switzerland thereby 
lowering the probability that three or more measurements 
were of high enough quality for an A or B rating to occur. 
Site investigators in Switzerland generally stopped repeating 
the measurements when a diagnosis of COPD was confirmed 
whereas in The Netherlands the investigators aimed for qual-
ity grades A or B by having more repeated measurements to 
obtain a more reliable measurement. Potential differences 
in measurement error are currently being investigated by 
analyzing the exact measurement variability between the 
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Table 6 Laboratory results among 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort N = 411) 
enrolled in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts prospective 
cohort study
Dutch cohort Swiss cohort Total cohort
Creatinine (µmol/L) p5, p50, p95 48, 72, 126 63, 88, 142 50, 77, 132
Bilirubin (µmol/L) p5, p50, p95 4, 8, 15 4, 8, 21 4, 8, 16
ALAT (U/L) p5, p50, p95 11, 21, 56 12, 24, 52 12, 22, 52
Total cholesterol (mmol/L) p5, p50, p95 3.4, 5.3, 7.5 3.9, 5.8, 7.9 3.5, 5.5, 7.7
HDL cholesterol (mmol/L) p5, p50, p95 0.9, 1.5, 2.3 0.9, 1.5, 2.4 0.9, 1.5, 2.3
LDL cholesterol (mmol/L) p5, p50, p95 1.5, 3.1, 5.0 1.3, 3.3, 5.3 1.5, 3.2, 5.1
Triglycerides (mmol/L) p5, p50, p95 0.6, 1.3, 3.2 0.7, 1.7, 4.2 0.6, 1.4, 3.8
CRP (mg/L) p5, p50, p95 1.0, 3.7, 22.6 0.4, 2.6, 21.7 0.8, 3.3, 22.2
COHb (%) p5, p50, p95 2.1, 3.5, 9.1 0.0, 1.6, 6.2 0.0, 2.9, 8.6
Leukocytes (10E9/L) p5, p50, p95 5.1, 7.7, 12.6 5.0, 8.1, 12.7 5.1, 7.8, 12.6
Notes: Reference values: creatinine male 75–110, female 65–95; bilirubin , 17; ALAT , 45; total cholesterol male 3.9–6.5, female 3.7–6.5; HDL cholesterol . 1.1; LDL 
cholesterol , 4.5; triglycerides 0.5–2; CRP , 5; COHb nonsmokers , 2%; smokers , 5%; toxic . 15%; leukocytes 4–10.5.
Abbreviations: ALAT, alanine aminotransferase; CRP, C-reactive protein; COHb, carboxyhemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; p5, fifth 
percentile; p50, median; p95, 95th percentile.
countries using intraclass correlations instead of ABCD 
ratings.
With regard to representativeness, some basic charac-
teristics (sex, age, pack years, FEV1% of predicted, and 
GOLD classification) of the ICE COLD ERIC cohort 
have been compared with two other COPD cohorts from 
the literature (Evaluation of COPD Longitudinally to 
Identify Predictive Surrogate Endpoints [ECLIPSE] and 
Investigating New Standards for Prophylaxis In Reducing 
Exacerbations [INSPIRE]).22,23 No differences were seen 
in age and pack years. In both the ECLIPSE and INSPIRE 
cohort, the percentage of males was larger (65% and 80%, 
respectively), the FEV1% of predicted was lower (48% and 
39%, respectively) and the prevalence of GOLD stage III 
(42% and 82%, respectively) and GOLD stage IV (14% and 
15%, respectively) was higher. Overall, the ECLIPSE and 
INSPIRE study included more severe COPD patients than 
the ICE COLD ERIC study, which can be explained by dif-
ferences in setting and inclusion criteria.22,23 The ICE COLD 
ERIC cohort is a representative cohort for COPD patients 
in primary care and may be used for purposes of worldwide 
collaboration on primary care data on COPD.24
One strength of the ICE COLD ERIC study is that it is 
an international prospective study with two cohorts from 
different countries linked by a single study protocol. Another 
strength of the study is that these cohorts were recruited in 
primary care and that the data collection is elaborate, espe-
cially with regard to comorbidity and drug use. Although 
the majority of COPD patients are managed in primary care, 
many previous cohorts were recruited in hospital settings or 
COPD clinics, which may reflect a COPD population with 
different characteristics. Also, comorbidities are often not 
properly reported in cohort studies. Patients from primary 
care represent a wide range of COPD severity and may 
have several coexisting diseases, which is also reflected in 
multifaceted therapies. The ICE COLD ERIC study cohorts 
will have an important contribution to (prognostic) research 
on COPD and characterizing COPD patients. The latter may 
be clinically important not only for its prognostic value but 
also for its therapeutic value, for a better understanding of 
the pathophysiology of COPD, and for genetic research in 
COPD. For example, responses to therapies such as the use 
of long-term oxygen or lung volume reduction surgery may 
differ between different (sub)types of patients.25–28
The rich variability within the ICE COLD ERIC cohorts 
offers many opportunities to learn more about the clinical 
course of COPD in a primary care population that represents 
the vast majority of COPD patients. The main purpose of the 
study is development and validation of practical prognostic 
COPD risk indices. Important risk predictors will be identified 
for dimensions of health-related quality of life, exacerbation 
risk, and mortality. For example, health-related quality of life 
was measured by the CRQ, which provides scores for four 
different domains. According to the score per domain, phy-
sicians may select treatment options for individual patients 
to improve their (domain-specific) health-related quality of 
life. Treatment decisions should be based on the needs of the 
individual patient, probably resulting in fewer unnecessary 
treatment prescriptions (for example, the widely prescribed 
inhaled corticosteroids in patients with mild disease), fewer 
exacerbations, and a better COPD-specific health-related 
quality of life. COPD management may also become more 
cost-effective by tailoring treatment decisions better to the 
needs of the individual patient.
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In a second step, evidence-based treatment effects 
mainly from randomized trials and meta-analyses will be 
incorporated, such that the instrument may guide   physicians 
in selecting treatment based on the individual patients’ 
prognoses. Ways to incorporate treatment advices into the 
prediction indices may be challenging and are currently being 
explored by this team. For example, a mortality risk of 30% 
for a COPD patient may be reduced to 24% by a certain treat-
ment if the relative risk reduction is 0.8. The absolute risk 
reduction is 6%. For another COPD patient with a mortality 
risk of 3%, that same treatment with a relative risk reduction 
of 0.8 will reduce the mortality risk to 2.4%, an absolute risk 
reduction of 0.6%. Adding cost considerations may lead to a 
recommendation to treat the former and not the latter patient. 
This is an example of risk-stratified treatment choices.
In summary, COPD patients in ICE COLD ERIC 
represent a wide range of disease severity and the prevalence 
of multimorbidity is high. These data show that the impact of 
COPD can be substantially different across patients even if 
lung function and the prevalence of comorbidities are quite 
similar. The rich variation in these prospective cohorts offers 
good opportunities to learn more about the clinical course 
of COPD in a primary care population representing the vast 
majority of COPD patients.
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